加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

奴卡菌脑膜脑炎一例报告

1 临床资料 患者，男，42岁，因记忆力减退，意识模糊 100 CDS 33．3％，CD28 56．5％川K细胞 12．5％。体液免疫：血清d，发热80d，于1998年7月29日人院。患者人院3年前，曾 l     

医学真菌学研究的现状与展望

医学真菌学是研究病原真菌和机会致病真菌对人类致病的机制、临床诊断、治疗和预防的一门重要学科。由于广谱抗生素、免疫抑制剂的广泛使用,导管插管、腹膜透析、放射治疗等大量开展,尤其是人类免疫缺陷病毒感染者的不断增多,真菌病尤其是深部真菌感染病例数日益增多,真菌病已成为影响     

硫唑嘌呤治疗大疱性类天疱疮致严重骨髓抑制2例

硫唑嘌呤用于某些皮肤病的治疗其主要不良反应为骨髓抑制、中毒性肝炎、胰腺炎和脱发等。笔者应用硫唑嘌呤治疗2例大疱性类天疱疮患者,在较短时间内发生严重的骨髓抑制,现报告如下。1病历摘要例1.男,65岁。因全身水疱1个月,于2002年1月30日收入我院。入院诊断为大疱性类天疱疮。入院后给予静脉滴注地塞米松10mg/d,同时加用复方倍他米松注射液(得宝松)1mL肌内注射。因皮损控制不理想,6周后加服硫唑嘌呤100mg/d。此时血常规检查示白细胞19.1×109/L,血红蛋白140g/L,血小板230×109/L。用药3d后无新发皮损出现,此期间每周复查血常规2次,用药1…     

肛周乳头状汗管囊腺瘤一例报告

临床资料　患者女 ,6 1岁。肛周暗褐色斑块伴瘙痒 3年 ,于 2 0 0 0年 3月 2 1日收治入院。患者自 1997年 4月始感肛周右侧出现花生米大小的斑块 ,左侧出现约黄豆大小的丘疹 ,伴轻度瘙痒。当地医院诊断为“内外痔、肛周湿疹”,中药口服、熏洗治疗无效。后肛周皮疹逐渐增大 ,期间外用“复方酮康唑软膏”、“高锰酸钾粉”治疗 ,瘙痒稍有减轻。系统检查未发现异常。皮肤性病科情况 :胸膝位于肛周 10点至 4点处有一片环绕肛门的半环状暗褐色斑块 ,紧贴肛门 ,宽约 3cm,表面粗糙 ,少量结痂 ,部分呈乳头状 ,边界清楚 ,质中 ,无压痛。实验室检查 :血…     

腰穿置管引流脑脊液加鞘内注药治疗隐球菌性脑膜炎6例

通过回顾性分析近年我科应用腰穿置管引流脑脊液加鞘内注药治疗的6例隐球菌性脑膜炎患者临床资料,探讨隐球菌性脑膜炎的治疗方法。结果6例患者全部治愈,其中初期治疗阶段即采用腰穿置管引流脑脊液加鞘内注药治疗的4例患者脑脊液隐球菌培养转阴时间为6~14d,平均10.2d。2例因不能系统应用两性霉素B而在治疗后期采用上述方法治疗的患者顺利完成全部疗程。腰穿置管引流脑脊液加鞘内注药治疗隐球菌性脑膜炎是有效的。     

面部难辨认癣1例并文献复习

难辨认癣临床表现多种多样,缺乏典型的浅部真菌感染的临床表现。现将笔者诊断的1例报告如下。1病例介绍患者,男,15岁,学生,因右面颊部红斑、丘疹伴瘙痒3个月余就诊。患者3个月前无明显诱因下右侧面部出现一拇指大小红斑,轻度瘙痒,未予重视,而后皮疹逐渐扩大,就诊于当地医院,考虑"面部皮炎",予"氢化可的松软膏(尤卓尔)"外用,